Filing Flows › Verastem (VSTM) › R&D spending
Verastem (VSTM) R&D spending by quarter
Verastem's R&D spending was $68.8M in Q3 2026 (third quarter 2026), +66% from Q2 2026. Over the last 6 quarters it ranged from $24.8M (Q2 2025) to $68.8M (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $68.8M | +66% | +137% |
| Q2 2026 | $41.3M | +8% | +67% |
| Q1 2026 | $38.2M | +21% | — |
| Q4 2025 | $31.7M | +9% | — |
| Q3 2025 | $29.0M | +17% | — |
| Q2 2025 | $24.8M | — | — |
Q3 2026 at a glance
Verastem, Q3 2026: revenue $24.0M (+114% year over year), operating margin -313.3%, net loss $74.7M, operating cash flow −$33.6M. The chart follows the revenue to costs, profit and cash.
Questions
What is Verastem's R&D spending?
Verastem's R&D spending was $68.8M in Q3 2026 (third quarter 2026), +66% from Q2 2026.
How has Verastem's R&D spending changed?
Over the last 6 quarters it ranged from $24.8M (Q2 2025) to $68.8M (Q3 2026).